By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the company's Byannli six-month maintenance treatment for schizophrenia in adults.
The drugmaker said the approval, which covers patients who are clinically stable on monthly or three-month doses, makes Byannli the first twice-yearly treatment of schizophrenia in adults in Europe.
The U.S. Food and Drug Administration in September approved a six-month version of the antipsychotic, marketed in the U.S. as Invega.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires